Dr Mohamed Elarabi

Dr. Mohamed Elarabi journey started at Mansoura University, Egypt, where he was awarded the Bachelor of Clinical Pharmacy in 2016 as an honour student ranked the seventh among 150 students. He then started his career as a volunteer clinical pharmacist at Mansoura University Urology & Nephrology Centre (UNC) for a few months, before joining the Mansoura University Gastrointestinal Surgery Center (GISC/GESC) to lead the establishment of their clinical pharmacy department and its clinical and teaching services. During this period, he also led a multi-disciplinary research team to find a therapy protocol for a killing EDR Acinetobacter baumannii nosocomial infection at the GISC/GESC.

In 2019, this clinical trial was published in the prestigious International Journal of Clinical Pharmacy and he completed his professional doctorate in clinical pharmacy (Pharm D), as an honour student as well, ranked the eighth among 100 students. In addition, he received a scholarship from the University of Sunderland that supported him to study the OSPAP MSc, that was awarded with distinction.

In 2020, he joined South Tyneside and Sunderland NHS Foundation Trust (STSFT) as a clinical pharmacist. Then in 2023, he joined Manchester University NHS Foundation Trust (MFT) and the University of Manchester as a specialist surgical pharmacist and a clinical tutor for undergraduate pharmacy and medicine students concomitantly.

In December 2024, Dr. Mohamed Elarabi joined ÃÛÌÒÖ±²¥ (ÃÛÌÒÖ±²¥) as a senior lecturer in pharmacy practice with a focus on postgraduate teaching.

Leicester Institute of Pharmaceutical Innovation for Integrated Care (LIPIIC)

• Elsayed, E., Elarabi, M.A., Sherif, D.A. et al. Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations. Int J Clin Pharm 42, 80–88 (2020).
• Elarabi, M.A. Answers to the authors of the “Letter to the Editor”: A comparative study between non colistin based combinations for treatment of infections caused by extensive drug resistant Acinetobacter baumannii: comments. Int J Clin Pharm 43, 1149–1151 (2021).

• Antimicrobial Resistance.
• Treatment Protocols Design.
• Drug Design.
• Clinical Education.

• Clinical Pharmacy Practice.
• Infections and Antimicrobial Therapies.

• Bachelor of Clinical Pharmacy (2016).
• Doctor of Pharmacy [Pharm. D] in Clinical Pharmacy (2019).
• OSPAP MSc (2020).
• Postgraduate Certificate in Clinical Pharmacy (2023).
• Postgraduate Diploma in Clinical Pharmacy Secondary and Tertiary Care (2025).

Clinical Pharmacy MSc/PG Dip/PG Cert programme (Advanced Therapeutics 2, Infections and Antimicrobial Therapies)

• General Pharmaceutical Council (GPhC) - Active Member.
• Royal Pharmaceutical Society (RPS) - Active Member.
• UK Clinical Pharmacy Association - Previous Member.
• Egypt's Pharmacists Syndicate (EPS) - Active Member.
• Dakahlia Pharmacists Syndicate (DPS) - Active Member.

• Registered Pharmacist - UK.
• Registered Pharmacist - Egypt.
• Brilliant Q2: Leadership & Culture (23/24) - MFT LH.
• Management and Leadership Skills - NHSE eLfH 2024.
• ICDL Certificate with HIS module.

• Developing new therapy protocol for EDR Acinetobacter Baumannii HAP in Mansoura University GISC/GESC [Lead Investigator].
• Auditing the diagnosis and treatment of suspected Clostridium difficile (C. diff) diarrhoea in Sunderland Royal Hospital (STSFT) - [Lead Investigator].
• Auditing the urine sample collection process before the initiation of antimicrobial therapy at Wythenshawe Hospital (MFT) - [Lead Investigator].